CLDX · Celldex Therapeutics, Inc.
$29.25
+0.97% last session
End-of-day data · close of 2026-10-23
Market cap
$2B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-6.9
Dividend yield
0.0%
Beta
0.90
Avg volume
1M
Employees
0K
Daily Change %
0.97%
5 Days Change
5.23%
10 Days Change
2.55%
30 Days Change
-6.91%
60 Days Change
-28.59%
Month to Day Change
-9.98%
Year to Day Change
6.66%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — CLDX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-02
Latest call per bank · past 12 months
Morgan Stanley
Overweight$57.00
+94.9% vs priceBarclays
Overweight$53.00
+81.2% vs priceWells Fargo
Overweight$72.00
+146.2% vs priceUBS
Buy$45.00
+53.8% vs priceGoldman Sachs
Neutral$34.00
+16.2% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-02 | HC Wainwright & Co. | Reiterates | Buy | $64.00 |
| 2026-09-23 | Leerink Partners | Maintains | Outperform | $70.00 → $88.00 |
| 2026-09-23 | Morgan Stanley | Maintains | Overweight | $50.00 → $57.00 |
| 2026-09-22 | HC Wainwright & Co. | Maintains | Buy | $42.00 → $64.00 |
| 2026-09-22 | Cantor Fitzgerald | Maintains | Overweight | $61.00 → $72.00 |
| 2026-09-10 | Morgan Stanley | Maintains | Overweight | $46.00 → $50.00 |
| 2026-08-07 | Morgan Stanley | Maintains | Overweight | $40.00 → $46.00 |
| 2026-08-07 | Barclays | Maintains | Overweight | $48.00 → $53.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 40 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 16.9% below the 50-day MA ($35.22).
- bearish: Price vs 200-day MA: Trading 10.2% below the 200-day MA ($32.57).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.28) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($22.58) and high ($44.87).
CLDX Price Chart
Loading chart for CLDX…
Fundamentals
About Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.